泌尿性器悪性腫瘍患者におけるPPD,PHAおよびSu-PS皮内反応について

Abstract

泌尿性器悪性腫瘍患者152症例の初回入院時PPD皮内反応が, 陽性群86例と凝陽性または陰性群65例の12ヵ月および36ヵ月の生存率は, それぞれ84.1%, 61.2%および65.0%, 30.6%であり, 両群間に有意差が認められた(p<0.005).腎細胞癌ではstage 1 10例とstage 4 13例の両群間に, PPD皮内反応に有意差が認められた(p<0.05).膀胱腫瘍症例では, low stage群はhigh stage群に比して, PPD皮内反応に対する陽性率が有意に高かった(p<0.05).死亡47例中に皮内反応の陰性化を示した症例がPPDでは10例(21.7%), Su-PSでは3例(13.0%)認められ, 死亡時皮内反応陰性症例は, PPD 32例(69.6%), PHA 4例(66.7%), Su-PS 17例(73.9%)であった

PPA, PHA and Su-PS skin tests were performed on 152 urogenital malignancy patients and the results obtained were analysed in terms of clinical course. The survival rate of 86 patients showing a positive response to the PPD skin test was significantly higher (P less than 0.005) than that of 65 patients showing a negative response to the PPD skin test. Among the 33 renal tumor patients, the positive rate of the 10 patients with stage I tumors to PPD skin test was significantly higher (P less than 0.05) than that of the 13 patients with stage IV tumors. In 68 bladder tumor patients, the response rate to PPD skin test in 47 patients with a low stage tumor was significantly high (P less than 0.05) compared with that in 21 patients with a high stage tumor. Out of 47 patients who died during the 84-month observation period, 10 (21.7%) and 3 (13.3%) showed a response change from negative to positive, in the PPD test and Su-PS test, respectively. It was assumed that 32 of the 46 patients (69.6%), 4 of the 6 patients (66.7%) and 17 of the 23 patients (73.9%) submitted to the PPD, PHA and Su-PS tests, respectively, showed a negative response at the time of their death.